Movement disorders represent a heterogenous group of neurodegenerative and genetic diseases of the brain with very different clinical presentations challenging the clinician concerning diagnosis and treatment. Advanced neuro-imaging techniques including MRI, MEG, SPECT and PET, neuropsychological, genetic and autonomic testing and Vicon 612 gait analysis system are available for diagnostic procedures. Advanced pharmacological Apomorphine and Duodopa pump treatment of Parkinson’s disease and stereotactical surgical electrode implantation to perform deep brain stimulation (DBS) for Parkinson’s disease, tremor and dystonia have been offered since 1996.
Stroke is a leading cause of disability. The Stroke Unit is a specialised and combined acute stroke unit and outpatient transient ischemic attack clinic. A fast multimodal MRI is first choice imaging modality. Key factors for successful treatment are extensive teamwork with pre-hospital service and rehabilitation hospitals and a multidisciplinary approach. We use fast track diagnostics as well as continuously updated and evidence based or experimental treatments in close collaboration with neuroradiologists. Intravenous thrombolysis and/or endovascular treatments are performed in about 300 patients annually.
Neuropathic pain is pain caused by lesions or specific diseases affecting the peripheral and central nervous system. These disorders, which include a series of diseases such as trigeminal neuralgia, nerve lesions, neuropathies, amputations and central pain conditions due to spinal cord injury, stroke, MS etc., represent challenges not only in terms of diagnosis but also in terms of underlying mechanisms and management. We use advanced types of pharmacological and non-pharmacological programmes including implantation of spinal cord stimulators to manage these types of pains. Specific laboratory for sensory examination and autonomic functions is available in the research unit and results here are implemented in the clinical management. All treatments are evidenced based and usually preceded by quantitative sensory testing.
Neuromuscular disorders comprise a large group of hereditary and acquired diseases resulting in sensory, motor and autonomic deficits. In a growing number of these disorders treatment has become possible and we use cutting edge treatment modalities such as immune-modulatory therapies and enzyme replacement therapy. Treatments are evidence based and based on close monitoring of neuromuscular function using standardised clinical evaluations and advanced quantitative techniques such as isokinetic dynamometry and MRI.